VCM
ADCT icon

Voleon Capital Management’s ADC Therapeutics ADCT Stock Holding History

Voleon Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93M Buy
513,831
+49,672
+11% +$196K 0.04% 338
2025
Q4 		$1.64M Buy
464,159
+393,848
+560% +$1.6M 0.04% 365
2025
Q3 		$281K Buy
+70,311
New +$222K 0.01% 738

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voleon Capital Management's ADCT Position: Q1 2026 in Review

Voleon Capital Management increased its ADC Therapeutics (ADCT) stake by 11% in Q1 2026, buying an estimated $196K and bringing the position to 513,831 shares worth $1.93M. The position accounts for 0.04% of the portfolio, ranked #338.

Voleon Capital Management first reported a position in ADCT in Q3 2025 and has held it in 3 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Voleon Capital Management held 513,831 shares of ADC Therapeutics worth $1.93M as of Q1 2026.
  • Voleon Capital Management bought 49,672 ADC Therapeutics shares in Q1 2026, an estimated $196K.
  • ADC Therapeutics made up 0.04% of Voleon Capital Management's portfolio in Q1 2026, its #338 holding.
  • Voleon Capital Management first reported a position in ADC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.